Abstract
Parkinson’s disease is a common neurodegenerative disease affecting the movement and well-being of most elderly. The manifestations of Parkinson’s disease often include resting tremor, stiffness, bradykinesia, and muscular rigidity. The typical hallmark of Parkinson’s disease is the destruction of neurons in the substantia nigra and the presence of Lewy bodies in different compartments of the central nervous system. Due to various limitations to the currently available treatments, immunotherapies have emerged to be the new approach to Parkinson’s disease treatment. This approach shows some positive outcomes on the efficacy by removing the aggregated species of alpha-synuclein, which is believed to be one of the causes of Parkinson’s disease. In this review, an overview of how alpha-synuclein contributes to Parkinson’s disease and the effects of a few new immunotherapeutic treatments, including BIIB054 (cinpanemab), MEDI1341, AFFITOPE, and PRX002 (prasinezumab) that are currently under clinical development, will be discussed.
Keywords: Parkinson's disease, alpha-synuclein, immunotherapies, BIIB054, MEDI1341, AFFITOPE PRX002.
CNS & Neurological Disorders - Drug Targets
Title:Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
Volume: 20 Issue: 9
Author(s): Jet Shee Teng, Yin Yin Ooi, Soi Moi Chye, Anna Pick Kiong Ling and Rhun Yian Koh*
Affiliation:
- Division of Applied Biomedical Science and Biotechnology, School of Health Science, International Medical University, Kuala Lumpur,Malaysia
Keywords: Parkinson's disease, alpha-synuclein, immunotherapies, BIIB054, MEDI1341, AFFITOPE PRX002.
Abstract: Parkinson’s disease is a common neurodegenerative disease affecting the movement and well-being of most elderly. The manifestations of Parkinson’s disease often include resting tremor, stiffness, bradykinesia, and muscular rigidity. The typical hallmark of Parkinson’s disease is the destruction of neurons in the substantia nigra and the presence of Lewy bodies in different compartments of the central nervous system. Due to various limitations to the currently available treatments, immunotherapies have emerged to be the new approach to Parkinson’s disease treatment. This approach shows some positive outcomes on the efficacy by removing the aggregated species of alpha-synuclein, which is believed to be one of the causes of Parkinson’s disease. In this review, an overview of how alpha-synuclein contributes to Parkinson’s disease and the effects of a few new immunotherapeutic treatments, including BIIB054 (cinpanemab), MEDI1341, AFFITOPE, and PRX002 (prasinezumab) that are currently under clinical development, will be discussed.
Export Options
About this article
Cite this article as:
Teng Shee Jet, Ooi Yin Yin, Chye Moi Soi , Ling Pick Kiong Anna and Koh Yian Rhun *, Immunotherapies for Parkinson’s Disease: Progression of Clinical Development, CNS & Neurological Disorders - Drug Targets 2021; 20 (9) . https://dx.doi.org/10.2174/1871527320666210526160926
DOI https://dx.doi.org/10.2174/1871527320666210526160926 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pharmacological Treatment in Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab
Current Rheumatology Reviews Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Heart Failure in South America
Current Cardiology Reviews Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond
Current Topics in Medicinal Chemistry Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Current Pharmaceutical Design Peptidomimetic Inhibitors of Cathepsin K
Current Topics in Medicinal Chemistry Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets Micropropagation: A Tool for the Production of High Quality Plant-based Medicines
Current Pharmaceutical Biotechnology Mitochondrial Dysfunction in Huntington’s Disease: Pathogenesis and Therapeutic Opportunities
Current Drug Targets Critical Issues in Delivery of RNAi Therapeutics In Vivo
Current Pharmaceutical Biotechnology Cardiovascular Magnetic Resonance Imaging: State of the Art
Current Cardiology Reviews Non-Selective Cation Channel Blockers: Potential Use in Nervous System Basic Research and Therapeutics
Mini-Reviews in Medicinal Chemistry The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy
Current Pharmaceutical Design Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications
Current Medicinal Chemistry Real-world Utilisation of the Rivastigmine Transdermal Patches Accompanying the Use of Risk Minimisation Tools in Patients with Dementia
Current Alzheimer Research